Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites. The ...

Medically reviewed by Gagandeep Brar, MDLung cancer is one of the most common types of cancer in the United States and a ...

Liquid biopsy is ... fluids for cancer cells. Experts suggest that liquid biopsies are becoming more widely recognised, especially when it comes to diagnosing and treating lung cancer.

Lung cancer arises in tissues of the lung, usually in the cells lining air passages. The two main types are small-cell lung cancer and non-small-cell lung cancer, according to the shape of cells ...

SGMC Health has successfully performed its first robotic-assisted lung biopsy using the state-of-the-art Ion robot. The health system said the procedure marked a major advancement in lung cancer ...

A lung biopsy involves the removal of tissue or growths from the lungs. A doctor will use special devices, such as a fine needle, to remove the sample. A lung biopsy can help diagnose lung ...

A lung biopsy is a procedure that involves removing ... looks like under a microscope and how it compares to healthy cells.

Lung cancer is usually confirmed with a biopsy. Your doctor will also determine ... Alecensa is used to treat non-small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive.

Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.

Jan. 26—MORGANTOWN — The WVU Cancer Institute is the first provider in the state to offer a new and promising treatment for extensive-stage small cell lung cancer.